BABA
Alibaba Group Holding Limited
BABA has a slight edge over CZR overall, supported by stronger modeled upside.
CZR
Caesars Entertainment, Inc.
CZR has slightly lower modeled downside risk, despite its lower overall score.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
CZR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Under pressure |
CZR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
CZR PE Valuation
CZR has no meaningful PE right now: it lost money over the past year.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over CZR on the outlook, with more favorable earnings and revenue expectations.
CZR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect CZR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA has the edge over CZR on earnings quality, reporting a profit while its opponent remains loss making.
CZR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.61 | -$1.45 |
| Q2 2026 | -$2.27 | -$1.34 |
| Q1 2026 | -$2.36 | -$1.26 |
| Q4 2025 | -$2.42 | -$1.13 |
| Q3 2025 | -$1.16 | +$0.50 |
| Q2 2025 | -$0.93 | +$0.35 |
| Q1 2025 | -$1.10 | -131% |
| Q4 2024 | -$1.29 | -135% |
CZR is still losing money, but far less than before: $2.61 per share over the past year, against $13.50 at its worst in late 2020.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA has the edge over CZR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA's operating margin was 7.2% last quarter, down 6.9 points from the same quarter a year ago.
CZR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +2.5% |
| Q2 2026 | $3B | +3% |
| Q1 2026 | $2.9B | +2.7% |
| Q4 2025 | $2.9B | +4.2% |
| Q3 2025 | $2.9B | -0.2% |
| Q2 2025 | $2.9B | +2.7% |
| Q1 2025 | $2.8B | +1.9% |
| Q4 2024 | $2.8B | -0.9% |
CZR's revenue grew through 2022 and has held roughly level since: $2.9B last quarter, up 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.3 points |
| Q2 2026 | 17% | -0.9 points |
| Q1 2026 | 17% | 0 points |
| Q4 2025 | 11% | -13 points |
| Q3 2025 | 18% | -4.5 points |
| Q2 2025 | 18% | +0.2 points |
| Q1 2025 | 17% | -0.2 points |
| Q4 2024 | 24% | +4.9 points |
CZR has the edge over BABA on profitability, with a higher operating margin.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
CZR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $95M | -23% |
| Q2 2026 | $304M | +31% |
| Q1 2026 | $36M | +$41M |
| Q4 2025 | $147M | +390% |
| Q3 2025 | $123M | +$315M |
| Q2 2025 | $232M | +86% |
| Q1 2025 | -$5M | +$179M |
| Q4 2024 | $30M | -78% |
CZR has the edge over BABA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has 2.4B diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
CZR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.4% | -3M shares |
| 3 years | -5.6% | -12M shares |
| 5 years | -4.7% | -10M shares |
| Available history | +162% | +126M shares |
CZR has the edge over BABA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $50M |
| Q3 2025 | $79M |
| Q4 2024 | $50M |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over CZR on leverage, with a lower net debt burden relative to earnings.
CZR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.3x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.3x | Elevated |
| Q4 2025 | 3.3x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.1x | Elevated |
CZR's net debt is about 3.3 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
CZR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.6 | Neutral |
CZR's weekly RSI is 55 (neutral) and its Stochastic is 39 (neutral).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA is trading at 21x earnings, a 19% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
CZR PE vs Consumer Cyclical Sector
| Metric | CZR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CZR has no meaningful PE right now: it lost money over the past year.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
CZR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.2 | 0.1% above |
| 20 week MA | $29.6 | 1.1% below |
| 50 week MA | $27.3 | 7.2% above |
| 100 week MA | $27.6 | 6.3% above |
| 200 week MA | $35.7 | 18% below |
CZR has the edge over BABA on trend strength, trading above more of its moving averages.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
CZR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.2 | $75.8 | +28% |
| 2021 | $75.8 | $94.8 | +25% |
| 2022 | $94.8 | $43.1 | -55% |
| 2023 | $43.1 | $46.9 | +8.8% |
| 2024 | $46.9 | $33.1 | -29% |
| 2025 | $33.1 | $24.8 | -25% |
| 2026 YTD | $24.8 | $29.3 | +18% |
CZR has the edge over BABA on returns for 2026, with the stronger performance.